US Tariff concerns: Jefferies explains why Sun Pharma could face the biggest hit
The Jefferies report on Sun Pharma reveals potential risks from US tariffs on medicines, but suggests the impact may be limited. Sun Pharma's reliance on innovative medicines puts it at risk, but its overseas manufacturing and exemption for generics offer some protection. The report recommends buying Sun Pharma with a target price of Rs 2,100.